Search This Blog

Wednesday, October 7, 2026

Mamdani’s tone-deaf Oct. 7 post attacks Israel for ‘ongoing genocide’

 Mayor Zohran Mamdani sparked outrage Wednesday by using the third anniversary of the Oct. 7 slaughter of Israelis to instead attack the Jewish state of “war crimes” in an “ongoing genocide.”

Hizzoner dedicated less than a quarter of his statement to the “unthinkable loss” suffered when “Hamas killed more than 1,100 Israelis and abducted 251 others” — with the vast majority instead devoted to his ongoing attacks on Israel.

“The suffering did not begin nor end that day. It instead continued through the Israeli government’s devastating, ongoing genocide in Gaza,” he said, decrying the Palestinians killed in response to the Hamas attack being marked Wednesday.

Naama Levy is taken hostage, Oct. 7, 2023. Levy was awakened by a missile barrage during the Hamas attack on Israel before sending a final message to her mother.

“That suffering has intensified with every Israeli bomb dropped on ambulances waiting outside hospitals, every drone strike targeting a residential building or journalist, and every shipment of food aid turned away at a border crossing.

“Three years later, we must refuse to accept a world in which occupation and apartheid continue, where war crimes are met with impunity, and our federal government continues its complicity with every arms shipment,” said Mamdani.

The biased statement by the mayor — already widely criticized for making Jewish New Yorkers feel unsafe with his ongoing attacks on Israel — was quickly met with horror.

“What he is trying to do is hijack the only day we have for the victims and survivors. He’s trying to hijack the day to talk about attacking Israel,” Israeli UN Ambassador Danny Danon told The Post:

“It’s like on 9/11 you talked about victims and al-Qaeda terrorists. It’s basically taking the only day we have for victims and trying to attack Israel with propaganda. He’s dangerous and sophisticated. He will go to both ceremonies and try to say he feels for both losses of life.”

Blood is seen splattered in a child’s room following a massive Hamas militant attack in Kibbutz Nir Oz, Israel.AP
Menashe Shapiro, a former adviser to Mamdani’s predecessor, former Mayor Eric Adams, called the statement “incitement and electronic violence against New York’s Jews.”

“He doesn’t get to hide behind Hamas’ made-up stats to justify his open Jew-hatred.”

https://nypost.com/2026/10/07/us-news/nyc-mayor-mamdani-uses-3rd-anniversary-of-oct-7-atrocity-to-attack-israel-for-ongoing-genocide/

France summons Iran envoy over 'disinformation'

 France summoned Iran's ambassador in Paris on Wednesday, at the request of Foreign Minister Jean-Noel Barrot, over what Paris called a "disinformation campaign" concerning the high school student movement in France.

The ambassador was told of the "absolutely unacceptable nature of the false content" shared online by official Iranian foreign ministry accounts, and of the "unfounded" summoning of France's ambassador in Tehran on Tuesday. France warned that these "unworthy provocations must cease."

Hours earlier, French Interior Minister Laurent Nunez denied accusations of excessive police force during the protests.

https://breakingthenews.net/Article/France-summons-Iran-envoy-over-'disinformation'/67252903

Pharma lobby sues Trump administration over Medicare drug price cuts

 The pharmaceutical industry’s top lobby group on Wednesday sued to invalidate the Trump administration’s efforts to benchmark US drug prices to lower costs overseas in the Medicare health insurance program, arguing that it is an illegal government overreach.

The ​GLOBE rule intends to set hospital drug prices for Medicare patients. Its final version ‌was published last week on exactly how a “most-favored-nation” pricing system based on what is paid in a group of comparable countries would be integrated in the Medicare Part B program.

The PhRMA lobby group filed its lawsuit in the US District Court for the District of Columbia against Health Secretary Robert F. Kennedy Jr., the US Department of Health and ‌Human ​Services he runs, and the Centers for Medicare & Medicaid Services and ⁠two of its officials.

The lobby group ⁠argues in its lawsuit that CMS, Medicare’s regulator, has stretched the authority of a program to test new pricing ideas into rewriting Medicare’s pricing structure without congressional action.

Congress has given CMS “a little bit of authority to test models,” PhRMA General Counsel Jim Stansel said in an interview. “Instead, ​CMS is doing exactly what Congress has declined to do multiple times over the last several years, and that’s to replace the pricing structure in Medicare with a most-favored-nation structure.”

Medicare is the ⁠US government program that provides health coverage to about 70 ⁠million people aged 65 and older or with disabilities.

HHS was not immediately ​available to comment on the lawsuit. In the finalized version of the rule, however, the agency argued that ​it was not overstepping its bounds, writing, “CMS is acting within a detailed, purpose ‌specific statutory framework that Congress designed precisely for this type of model test.”

The rule is expected to have limited reach. CMS plans to waive the requirement for manufacturers that have signed separate deals with the White House to participate in the price-setting model, according to the rule. Trump has already signed deals ⁠with more than two dozen drugmakers, including many of the world’s largest, such as Pfizer, Eli Lilly and Novo Nordisk.

The pricing regime may ultimately apply to as few as four drugmakers after exempting those ⁠companies.

The final rule also sharply reduced ‌the government’s projected savings from the model. HHS now estimates the program ⁠will reduce Medicare Part B spending by about $440 million over the 7-year ​model period, ‌compared with roughly $11.9 billion projected in the proposed rule published last ​year.

In 2020, PhRMA ⁠successfully sued to block a previous incarnation of most-favored-nation pricing, but that rule was invalidated on procedural grounds because the administration had rushed it out without giving the public a chance to comment.

Also named in the suit were CMS Administrator Dr. Mehmet Oz, the agency’s innovation center that is running the most-favored-nation pricing pilot and the director of that division, Abe Sutton.

https://wkzo.com/2026/10/07/pharmaceutical-trade-group-sues-trump-administration/

FDA grants two Breakthrough Therapy Designations to AbbVie

 investigational ADC telisotuzumab adizutecan (Temab-A) in colorectal and non-small cell lung cancer

https://finviz.com/stock?t=ABBV&p=d

'Iran MP accuses IAEA chief Grossi of providing pretext for attacks on Iran'

 

Reports by International Atomic Energy Agency chief Rafael Grossi provided a pretext for attacks on Iran, a lawmaker said on Wednesday.

“Rafael Grossi’s reports, which have often been inaccurate, have become a pretext and justification for attacks on Iran,” Mohammad Rashidi said.

He also said that Iran’s cooperation with the agency depended on it meeting its obligations to the country.

https://www.iranintl.com/en/202610076347

'One-third of Iran’s lawmakers to attend parliament in person next week, MP says'

 

About one-third of Iran’s lawmakers are expected to attend parliamentary sessions in person from next week, while others will be able to speak and vote remotely by tablet, lawmaker Valiollah Bayati said on Wednesday.

The presiding board’s current plan is for each parliamentary committee to select three members to attend in person on a rotating basis, Bayati said. The arrangement has not been finalized, but it would allow all lawmakers to attend in person at some point during the month.

Lawmakers want to hold in-person sessions, he said, but current wartime conditions do not allow all 275 members to gather in one place.

https://www.iranintl.com/en/202610074173

'Iran lawmaker warns of winter power and gas cuts in northern provinces'

 

Electricity and gas cuts may affect Iran’s northern provinces this winter, said lawmaker Mehrdad Lahouti, who represents Langarud in northern Iran.